Latest Production Development News

Osteopore Limited has secured non-exclusive distribution rights for an injectable regenerative bone filler across Southeast Asia, marking a strategic expansion of its orthopaedic product portfolio and opening new revenue channels.

HighCom Limited has successfully raised nearly $800,000 through a Share Purchase Plan, adding to a prior $7 million placement to fund product upgrades and sales growth.

Cadoux Ltd has secured a $600,000 milestone payment from the Western Australian Government’s Investment Attraction Fund, marking significant progress in its high purity alumina project development.

Argosy Minerals reports strong progress on its 12,000 tonnes per annum Rincon Lithium Project in Argentina, achieving 96% lithium recovery in test work and advancing critical energy infrastructure with a 40MW power supply line.

Felix Group Holdings has appointed seasoned tech leader Chris Atkin as CEO, aiming to drive growth and integrate its Nexvia platform. Atkin’s track record in scaling SaaS businesses signals a strategic push for disciplined expansion.

Advanced Braking Technology Ltd has reported a record half-year performance for 1H26, driven by strong demand for its SIBS Failsafe braking systems and progress in autonomous braking technology.

Argosy Minerals reports a 96% lithium recovery from test works at its Rincon Lithium Project and progresses critical energy infrastructure, moving closer to a final investment decision.

Complii FinTech Solutions reported a $1.35 million loss for H1 FY26 alongside a 6% increase in annual recurring revenue, driven by strategic platform upgrades and expanding client engagement.

Norwood Systems Limited reported a significant revenue increase for the half-year ended December 2025, alongside a widening net loss and strategic progress with Tier-1 telecom customers. The company secured additional funding and advanced its AI-driven voice platforms in collaboration with global hyperscalers.

KneoMedia Limited reported a half-year loss of $1.02 million for H1 FY26, impacted by delayed payments from New York City amid a mayoral transition. The company is preparing for ASX reinstatement and a $3 million capital raise to support growth.

Osteopore Limited reported an 11% increase in revenue to $3.06 million for 2025, alongside a wider net loss of $3.72 million as it invests heavily in product development and regulatory compliance. The company also expanded its footprint with a new Singapore subsidiary.

Nexalis Therapeutics reported a widening loss of $1.83 million for 2025, reflecting increased investment in product development and marketing. Despite the loss, the company boosted its cash reserves through equity raises and borrowings.